These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6267005)

  • 21. 'Beta-lactams' as beta-lactamase inhibitors.
    Cole M
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):207-23. PubMed ID: 6109317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics.
    Melchior NH; Keiding J
    J Antimicrob Chemother; 1991 Jan; 27(1):29-40. PubMed ID: 1646779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A semi-synthetic penicillinase inactivator.
    Cartwright SJ; Coulson AF
    Nature; 1979 Mar; 278(5702):360-1. PubMed ID: 218114
    [No Abstract]   [Full Text] [Related]  

  • 24. In-vitro susceptibility of beta-lactamase-producing Haemophilus influenzae to the combinations ampicillin with mecillinam and ampicillin and VD2085.
    Piot P; van Dyck E
    J Antimicrob Chemother; 1985 Dec; 16(6):808-9. PubMed ID: 3005221
    [No Abstract]   [Full Text] [Related]  

  • 25. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
    Jarlier V
    Presse Med; 1998 Sep; 27 Suppl 4():17-8. PubMed ID: 9798480
    [No Abstract]   [Full Text] [Related]  

  • 26. Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.
    Farmer TH; Degnan BA; Payne DJ
    FEMS Microbiol Lett; 1999 Jul; 176(1):11-5. PubMed ID: 10418127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-Lactamase inhibitory activity of iodopenicillanate and bromopenicillanate.
    Neu HC
    Antimicrob Agents Chemother; 1983 Jan; 23(1):63-6. PubMed ID: 6299186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH; Smith SM; Cherubin CE
    J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
    [No Abstract]   [Full Text] [Related]  

  • 31. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
    Kempers J; MacLaren DM
    J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
    [No Abstract]   [Full Text] [Related]  

  • 34. Methylene (2S,5R)-6-(3-formylallylidene)penicillanate pivalate, a prodrug of a new beta-lactamase inhibitor.
    Adam S; Then R; Angehrn P
    J Antibiot (Tokyo); 1992 Apr; 45(4):587-8. PubMed ID: 1317369
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiological properties of sulbactam combined with ampicillin.
    Barba D; Galante D; Esposito S; Ruffilli MP
    Chemioterapia; 1987 Apr; 6(2):88-94. PubMed ID: 3036381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
    Corkill JE; Hart CA; McLennan AG; Aspinall S
    J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacteriological investigations with beta-lactamase inhibitors.
    Ullmann U
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):222-9. PubMed ID: 6289565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
    Henson KE; Yim J; Smith JR; Sakoulas G; Rybak MJ
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.